BRUSSELS, Belgium, April 17, 2026

UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, marking a major strategic expansion into regenerative medicine and advanced cell therapies for neurological disorders. The acquisition strengthens UCB’s long-standing leadership in epilepsy treatment and introduces a promising clinical-stage neuronal cell therapy, NRTX-1001, into its pipeline.

Strategic Entry into Regenerative Medicine and Cell Therapy

The acquisition represents a significant milestone in UCB’s evolution toward next-generation disease-modifying therapies, moving beyond traditional symptom management in neurological conditions. By integrating Neurona’s pluripotent stem cell-based platform, UCB is expanding into regenerative neuroscience, aiming to deliver long-lasting therapeutic benefits through targeted neural repair.

At the center of the deal is NRTX-1001, an investigational neuronal cell therapy currently being evaluated in Phase I/II clinical trials for drug-resistant mesial temporal lobe epilepsy (MTLE). This innovative therapy is administered as a single, minimally invasive dose مباشرة into the brain, where it introduces GABA-producing inhibitory neurons to restore balance in overactive neural circuits.

This approach represents a paradigm shift in epilepsy treatment, offering the potential for durable seizure reduction rather than ongoing symptomatic control, addressing a critical unmet need for patients who do not respond to existing therapies.

Advertisement

cGxPJobs Banner

Clinical Potential and Regulatory Recognition

The lead asset NRTX-1001 has already demonstrated encouraging early clinical data, supporting its continued development as a first-in-class regenerative therapy. Importantly, the therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA and PRIME designation from the European Medicines Agency (EMA), highlighting its potential to address serious unmet medical needs and benefit from accelerated regulatory pathways.

The ongoing clinical trials are evaluating safety, tolerability, and efficacy, including reductions in seizure frequency in patients with severe epilepsy. These designations not only validate the scientific approach but also position the therapy for faster clinical and regulatory progression, enhancing its potential to reach patients sooner.

Given that temporal lobe epilepsy is the most common form of focal epilepsy, often associated with significant cognitive and behavioral impairments, the development of a disease-modifying therapy could significantly improve quality of life and long-term outcomes.

Expanding Biopharma Innovation Through M&A Strategy

The transaction includes an upfront payment of $650 million, with up to $500 million in milestone-based payments, reflecting UCB’s commitment to innovation-driven growth and strategic acquisitions. The deal is expected to close by mid-2026, pending regulatory approvals.

This acquisition aligns with broader industry trends toward biopharmaceutical consolidation and investment in advanced therapeutic modalities, including cell therapy, gene therapy, and regenerative medicine. By leveraging Neurona’s platform and expertise, UCB aims to accelerate the development of transformative therapies across neurological diseases.

Furthermore, the integration of Neurona’s technology enhances UCB’s R&D pipeline diversification, enabling the company to address complex central nervous system disorders with innovative biological approaches.

The acquisition of Neurona Therapeutics marks a transformational step for UCB, reinforcing its leadership in epilepsy and neurological innovation while advancing into the rapidly evolving field of regenerative medicine. With NRTX-1001 and its cutting-edge cell therapy platform, UCB is poised to deliver next-generation treatments that go beyond symptom control, offering hope for long-term disease modification in patients with severe epilepsy.

Source: UCB, Neurona Therapeutics press release